- Home
- ALTS vs PHGE Comparison
ALTS vs PHGE Comparison
Compare ALTS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- PHGE
- Stock Information
- Founded
- ALTS 1976
- PHGE 2015
- Country
- ALTS United States
- PHGE Israel
- Employees
- ALTS N/A
- PHGE N/A
- Industry
- ALTS
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- PHGE Health Care
- Exchange
- ALTS NYSE
- PHGE Nasdaq
- Market Cap
- ALTS 26.0M
- PHGE 26.5M
- IPO Year
- ALTS N/A
- PHGE N/A
- Fundamental
- Price
- ALTS $1.80
- PHGE $0.92
- Analyst Decision
- ALTS
- PHGE Strong Buy
- Analyst Count
- ALTS 0
- PHGE 2
- Target Price
- ALTS N/A
- PHGE $22.50
- AVG Volume (30 Days)
- ALTS 218.9K
- PHGE 48.2K
- Earning Date
- ALTS 11-12-2024
- PHGE 11-12-2024
- Dividend Yield
- ALTS N/A
- PHGE N/A
- EPS Growth
- ALTS N/A
- PHGE N/A
- EPS
- ALTS N/A
- PHGE N/A
- Revenue
- ALTS $2,169,000.00
- PHGE N/A
- Revenue This Year
- ALTS N/A
- PHGE N/A
- Revenue Next Year
- ALTS N/A
- PHGE N/A
- P/E Ratio
- ALTS N/A
- PHGE N/A
- Revenue Growth
- ALTS N/A
- PHGE N/A
- 52 Week Low
- ALTS $0.22
- PHGE $0.88
- 52 Week High
- ALTS $5.26
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- ALTS 41.37
- PHGE 29.22
- Support Level
- ALTS $1.70
- PHGE $0.88
- Resistance Level
- ALTS $1.89
- PHGE $1.15
- Average True Range (ATR)
- ALTS 0.15
- PHGE 0.07
- MACD
- ALTS -0.02
- PHGE 0.02
- Stochastic Oscillator
- ALTS 19.61
- PHGE 13.54
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.